Mabpharm (HKSE:02181) Research & Development: HK$63.3 Mil (TTM As of Dec. 2025)


HKSE:02181 Mabpharm Ltd HKSE:02181
38 GF Score
Price HK$0.40
GF Value HK$1.96
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Mabpharm Research & Development?

Mabpharm HKSE:02181 38 Research & Development is HK$63.3 Mil as of Dec. 2025. GuruFocus rates HKSE:02181 with a GF Score™ of 38/100 and a GF Value™ of HK$1.96 (Possible Value Trap). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Mabpharm's Research & Development for the six months ended in Dec. 2025 was HK$37.3 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$63.3 Mil.

Mabpharm  (HKSE:02181) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Mabpharm Research & Development Related Terms

Mabpharm Research & Development Historical Data

* Premium members only.

The historical data trend for Mabpharm's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mabpharm Research & Development Chart

Mabpharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 322.74 165.17 134.77 80.30 63.55

Mabpharm Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.66 60.60 20.20 26.03 37.25
HKSE:02181
38GF Score
Mabpharm Ltd HKSE:02181
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mabpharm Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$63.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$63.3 Mil mean?
Mabpharm (HKSE:02181) has a Research & Development of HK$63.3 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Mabpharm and its competitors.
Is Mabpharm's Research & Development too high?
Mabpharm's current Research & Development is HK$63.3 Mil. Overall, Mabpharm has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mabpharm's Research & Development compare to VRTX and REGN?
Mabpharm's Research & Development of HK$63.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Mabpharm and its competitors. Mabpharm's current Research & Development is HK$63.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabpharm stock overvalued right now?
Based on GuruFocus' analysis, Mabpharm (HKSE:02181) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.96, compared to a current price of HK$0.40 — trading 79.8% below its estimated fair value. The current Research & Development is HK$63.3 Mil. Mabpharm's overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Mabpharm (HKSE:02181), the current Research & Development is HK$63.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mabpharm (HKSE:02181) Overvalued in 2026?

Based on GuruFocus' analysis, Mabpharm stock appears to be undervalued. The current stock price of HK$0.40 is trading 79.8% below its estimated GF Value™ of HK$1.96. GuruFocus considers Mabpharm to be Possible Value Trap.

Key valuation signals for HKSE:02181:

  • Research & Development: HK$63.3 Mil
  • GF Value™: HK$1.96 vs. price of HK$0.40 (79.8% below fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the HKSE:02181 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mabpharm Business Description

Address Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab). Company operates in Chinese Mainland and Others.
38GF Score

Get the complete analysis for HKSE:02181

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.40
Price
HK$1.96
GF Value